Pharma Focus Asia

Boehringer Ingelheim Inaugurates the New High-tech Facility

Tuesday, April 25, 2023

Boehringer Ingelheim inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany.

The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.

The new facility is a highly complex building, offering modern workplaces for more than 500 employees who will develop Boehringer Ingelheim's future biopharmaceutical substances. Scientists from multiple disciplines and three different development units will collaborate under one roof to research and develop antibodies and therapeutic proteins.

The BDC is a building with a gross floor space of 34,500 sqm, which equals five football fields. The construction of the BDC is part of Boehringer Ingelheim's consistent future strategy with significant investments in its R&D pipeline, which amounted to 5 billion EUR in the last business year – 47 per cent alone in Germany.

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024